Grant Wishart PhD, Director CADD & Structural Biology, leads the Charles River CADD & Structural Biology groups, which provide computational chemistry, structural biology, biophysics and protein production services across partner drug discovery […]
Abraham Heifets was working at IBM Research on high performance data processing when his career interest veered toward drug discovery. A big data guy, he found himself studying organic chemistry—specifically chemical synthesis planning—and […]
Apply for the Artificial Intelligence Molecular Screening (AIMS) Awards Program The AIMS Award Program, started in 2017, is designed to support promising researchers with resources that will help advance their work. AIMS Awards target research […]
- by Stefan Schroedl, Head of Machine Learning at Atomwise Originally posted on Medium This post is intended for my fellow machine learning engineers who are curious about applications in medicine, biology, or chemistry, but without a prior formal […]
- by Stefan Schroedl, Head of Machine Learning at Atomwise Originally posted on Medium Introduction Having applied machine learning to search and advertising for many years, two years ago I was ready for a transition to something new. In particular, […]
To understand Atomwise, it helps to know a little about how drug discovery works.
What is AtomNet® technology? AtomNet® technology is the first drug discovery algorithm to use a deep convolutional neural network – the same AI technology that recognizes faces in a crowd enables self-driving cars, and allows you to talk to your […]
In November, Atomwise published the first scientific paper about our technologies – AtomNet® platform: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery. This blog post is an introduction to that work […]